Dermatomycoses Market Report 2026

Dermatomycoses Market Overview

• Dermatomycoses market size has reached to $14.81 billion in 2025 • Expected to grow to $19.11 billion in 2030 at a compound annual growth rate (CAGR) of 5.2% • Growth Driver: Increasing Prevalence Of Fungal Infections Fueling The Growth Of The Market Due To Rising Immunocompromised Population And Poor Hygiene • Market Trend: Advancements In Onychomycosis Treatment With Investigational New Drug Developments In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Dermatomycoses Market?

Dermatomycoses are a group of fungal infections affecting the skin, hair, and nails, primarily caused by dermatophytes, yeasts, or molds. These infections often lead to itching, scaling, redness, and skin inflammation, impacting overall skin health. The main goal of treatment is to eliminate the fungal infection, alleviate symptoms, and prevent recurrence through the use of antifungal medications, maintaining proper hygiene, and following effective skin care practices. The main drug types of dermatomycoses are corticosteroids, corticosteroid-sparing agents, immunosuppressive, immunomodulator, antifungals, others. Corticosteroids are anti-inflammatory drugs that help reduce swelling, redness, and itching in skin conditions. These are administered through various route of administration such as oral, parenteral, topical, others and are used by various end-users such as hospitals, specialty clinics, others.

What Is The Dermatomycoses Market Growth Forecast?

The dermatomycoses market size is expected to see strong growth in the next few years. It will grow to $19.11 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to improved antifungal formulations, increasing skin infection incidence, growing outpatient care, rising hygiene awareness, expansion of dermatology services. Major trends in the forecast period include rising prevalence of fungal skin infections, increased use of topical antifungals, growth of combination antifungal therapies, expansion of outpatient dermatology care, focus on recurrence prevention.

Global Dermatomycoses Market Segmentation

1) By Drugs: Corticosteroids, Corticosteroid-Sparing Agents, Immunosuppressive, Immunomodulator, Antifungals, Other Drugs 2) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administrations 3) By End-User: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids 2) By Corticosteroid-Sparing Agents: Tacrolimus, Pimecrolimus 3) By Immunosuppressive: Methotrexate, Azathioprine, Cyclophosphamide 4) By Immunomodulator: Interferon-Gamma, Thalidomide 5) By Antifungals: Topical Antifungals, Oral Antifungals, Systemic Antifungals 6) By Other Drugs: Antihistamines, Antibacterial Agents

What Are The Drivers Of The Dermatomycoses Market?

The increasing prevalence of fungal infections is expected to propel the growth of the dermatomycoses market going forward. Fungal infections are conditions caused by fungi that infect the skin, nails, hair, or internal organs, resulting in different health issues. The excessive use of broad-spectrum antibiotics disrupts the natural microbiome, allowing fungi to thrive and cause infections. This imbalance weakens the body's natural defense mechanisms, making individuals more vulnerable to opportunistic fungal infections. Dermatomycoses, caused by dermatophytes, yeasts, and molds, are responsible for fungal diseases, affecting various tissues and causing common superficial and systemic infections. For instance, in November 2023, according to the UK Health Security Agency, a UK-based public health agency responsible for protecting public health from infectious diseases, global estimates indicate an annual incidence of 6.5 million invasive fungal infections, resulting in approximately 3.8 million deaths, with 2.5 directly attributed to these infections. Therefore, the increasing prevalence of fungal infections drives the dermatomycoses industry. The growth in aging population is expected to propel the growth of the dermatomycoses market going forward. Aging population refers to the increasing number and proportion of individuals aged 65 years and older within a nation's demographic structure. The aging population is increasing because the large baby boomer generation is now reaching retirement age, leading to a higher proportion of elderly individuals in society. Growing aging populations support increased incidence of fungal skin infections as elderly individuals experience weakened immune systems, reduced skin barrier function, and age-related changes that make them more susceptible to dermatomycoses including athlete's foot, ringworm, and nail infections. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, there were 12.7 million individuals aged 65 or older in the UK, making up 19% of the total population. By 2072, this number is expected to increase to 22.1 million, comprising 27% of the population. Therefore, the growth in aging population is driving the growth of the dermatomycoses industry.

Key Players In The Global Dermatomycoses Market

Major companies operating in the dermatomycoses market are Pfizer Inc., Bayer AG, Saphnix Life Sciences, MITS Healthcare Private Limited, Weefsel Pharma, AdvaCare Pharma, Associated Biotech, Healthy Life Pharma Private Limited, Blueberry Therapeutics Ltd., Livealth Biopharma Pvt. Ltd., LGM Pharma, SiNi Pharma Pvt. Ltd., Joshi Agrochem Pharma Private Limited, Wellona Pharma, Abiba Pharmacia Pvt. Ltd., Vee Excel Drugs & Pharmaceuticals Pvt. Ltd., Femcorp Pharma, Lexicare Pharma Pvt. Ltd., Glamris Dermacare, Henin Lukinz

Global Dermatomycoses Market Trends and Insights

Major companies operating in the dermatomycoses market are focusing on investigational new drugs candidate to advance onychomycosis treatment and improve efficacy. An investigational new drug (IND) candidate is a pharmaceutical compound undergoing preclinical or clinical trials to evaluate its safety, efficacy, and potential for regulatory approval before becoming an approved treatment. For instance, in January 2024, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company received Investigational New Drug VTR-297 candidate for the treatment of onychomycosis approved by the US Food and Drug Administration (FDA), a US-based government agency. VTR-297 stands out as a topical antifungal candidate due to its histone deacetylase (HDAC) inhibitor properties, distinguishing it from traditional antifungal treatments. This works by targeting the root cause of fungal growth, demonstrating potent antifungal activity against dermatophytes and other fungi. This innovative mechanism of action has the potential to deliver faster and more effective treatment results while also reducing the likelihood of infection recurrence, addressing a significant unmet need in onychomycosis treatment.

Regional Outlook

North America was the largest region in the dermatomycoses market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Dermatomycoses Market?

The dermatomycoses market consists of sales of barrier creams or protective skin creams, medicated soaps and body washes, and cryotherapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Dermatomycoses Market Report 2026?

The dermatomycoses market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the dermatomycoses industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.